Marko A. Mychaskiw

642 total citations
32 papers, 485 citations indexed

About

Marko A. Mychaskiw is a scholar working on Psychiatry and Mental health, Pulmonary and Respiratory Medicine and Clinical Psychology. According to data from OpenAlex, Marko A. Mychaskiw has authored 32 papers receiving a total of 485 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Clinical Psychology. Recurrent topics in Marko A. Mychaskiw's work include Schizophrenia research and treatment (11 papers), Pulmonary Hypertension Research and Treatments (11 papers) and Bipolar Disorder and Treatment (5 papers). Marko A. Mychaskiw is often cited by papers focused on Schizophrenia research and treatment (11 papers), Pulmonary Hypertension Research and Treatments (11 papers) and Bipolar Disorder and Treatment (5 papers). Marko A. Mychaskiw collaborates with scholars based in United States, United Kingdom and Germany. Marko A. Mychaskiw's co-authors include Howan Leung, Teresa León, Patrick Kwan, Evelyn Yu, Kafi N. Sanders, Gerry Oster, Jack Mardekian, Ariel Berger, John Edelsberg and Xiaoqin Yang and has published in prestigious journals such as SHILAP Revista de lepidopterología, CHEST Journal and Ophthalmology.

In The Last Decade

Marko A. Mychaskiw

31 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marko A. Mychaskiw United States	12	266	100	92	66	58	32	485
A. S. M. Lim Netherlands	7	86 0.3×	12 0.1×	73 0.8×	35 0.5×	50 0.9×	14	430
M. Franz Germany	11	143 0.5×	10 0.1×	26 0.3×	11 0.2×	63 1.1×	27	452
Hellmuth Freyberger Germany	10	341 1.3×	43 0.4×	9 0.1×	188 2.8×	226 3.9×	42	752
Jerzy A Sobański Poland	10	86 0.3×	12 0.1×	14 0.2×	23 0.3×	121 2.1×	64	323
Amy E. Sanders United States	11	141 0.5×	20 0.2×	33 0.4×	40 0.6×	20 0.3×	18	444
Suraj Sarvode Mothi United States	12	115 0.4×	37 0.4×	33 0.4×	4 0.1×	106 1.8×	48	405
Diana Winston United States	7	35 0.1×	68 0.7×	70 0.8×	135 2.0×	143 2.5×	11	603
Eda Derle Türkiye	9	141 0.5×	77 0.8×	27 0.3×	83 1.3×	18 0.3×	28	340
Tarek A. Rageh Egypt	15	294 1.1×	190 1.9×	45 0.5×	3 0.0×	61 1.1×	33	593
C. Kalkavoura Greece	6	108 0.4×	38 0.4×	23 0.3×	3 0.0×	74 1.3×	6	363

Countries citing papers authored by Marko A. Mychaskiw

Since Specialization

Citations

This map shows the geographic impact of Marko A. Mychaskiw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marko A. Mychaskiw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marko A. Mychaskiw more than expected).

Fields of papers citing papers by Marko A. Mychaskiw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marko A. Mychaskiw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marko A. Mychaskiw. The network helps show where Marko A. Mychaskiw may publish in the future.

Co-authorship network of co-authors of Marko A. Mychaskiw

This figure shows the co-authorship network connecting the top 25 collaborators of Marko A. Mychaskiw. A scholar is included among the top collaborators of Marko A. Mychaskiw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marko A. Mychaskiw. Marko A. Mychaskiw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Citrome, Leslie, et al.. (2024). TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia. Neuropsychiatric Disease and Treatment. Volume 20. 1901–1917. 3 indexed citations

Correll, Christoph U., José M. Rubio, Leslie Citrome, et al.. (2024). Introducing S.C.O.P.E. : Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement An Interactive Digital Platform to Educate on Schizophrenia Care. CNS Spectrums. 29(5). 516–517. 1 indexed citations

Correll, Christoph U., José M. Rubio, Leslie Citrome, et al.. (2024). Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care. Neuropsychiatric Disease and Treatment. Volume 20. 1995–2010. 2 indexed citations

Kane, John M., et al.. (2023). Treatment Journey From Diagnosis to the Successful Implementation of a Long-Acting Injectable Antipsychotic Agent in Young Adults With Schizophrenia. The Journal of Clinical Psychiatry. 84(3). 9 indexed citations

Robinson, Delbert G., et al.. (2023). Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia. Advances in Therapy. 40(5). 2249–2264. 13 indexed citations

Kane, John M., et al.. (2023). Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. International Clinical Psychopharmacology. 38(4). 240–248. 9 indexed citations

Citrome, Leslie, et al.. (2022). Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians. Neuropsychiatric Disease and Treatment. Volume 18. 111–123. 15 indexed citations

Citrome, Leslie, et al.. (2022). Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study. SHILAP Revista de lepidopterología. 12 indexed citations

Yang, Xiaoqin, Kafi N. Sanders, Jack Mardekian, Marko A. Mychaskiw, & Joseph Thomas. (2015). Associations Between Sildenafil Use and Changes in Days of Hospitalization in a Population With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Clinical Therapeutics. 37(5). 1055–1063. 3 indexed citations

10.

Yang, Xiaoqin, Jack Mardekian, Kafi N. Sanders, Marko A. Mychaskiw, & Joseph Thomas. (2013). Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clinical Rheumatology. 32(10). 1519–1531. 56 indexed citations

11.

Berger, Ariel, et al.. (2012). Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. BMC Pulmonary Medicine. 12(1). 75–75. 22 indexed citations

12.

Berger, Ariel, John Edelsberg, Kafi N. Sanders, et al.. (2012). Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study. BMC Psychiatry. 12(1). 99–99. 33 indexed citations

13.

Rascati, Karen L., Kristin M. Richards, Carol A. Ott, et al.. (2011). Adherence, Persistence of Use, and Costs Associated With Second-Generation Antipsychotics for Bipolar Disorder. Psychiatric Services. 62(9). 1032–1040. 29 indexed citations

14.

Cappelleri, Joseph C., et al.. (2010). Physical Functioning, Six-Minute Walk Distance, and Pulmonary Vascular Resistance in Adult Patients With Pulmonary Arterial Hypertension Treated With Sildenafil: Examining the Distributions of Outcomes. CHEST Journal. 138(4). 362A–362A. 1 indexed citations

15.

Mychaskiw, Marko A., et al.. (2010). Relationship Between Pulmonary Vascular Resistance and Physical Functioning in Two Randomized Controlled Trials of Adult Patients With Pulmonary Arterial Hypertension, Including Those With Associated Connective Tissue Disease. CHEST Journal. 138(4). 363A–363A. 1 indexed citations

16.

Vera‐Llonch, Montserrat, Ellen Dukes, Javier Rejas, et al.. (2009). Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. The European Journal of Health Economics. 11(1). 35–44. 19 indexed citations

17.

Berger, Ariel, Marko A. Mychaskiw, Ellen Dukes, John Edelsberg, & Gerry Oster. (2009). Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder. BMC Geriatrics. 9(1). 31–31. 13 indexed citations

18.

Stewart, William C., et al.. (2008). Cost-effectiveness of Treating Ocular Hypertension. Ophthalmology. 115(1). 94–98. 32 indexed citations

19.

Schwartz, Gail F., Robert W. Platt, Gregory Reardon, & Marko A. Mychaskiw. (2007). Accounting for Restart Rates in Evaluating Persistence with Ocular Hypotensives. Ophthalmology. 114(4). 648–652. 36 indexed citations

20.

Murawski, Matthew M. & Marko A. Mychaskiw. (2003). The Academy's Public Responsibility. Journal of Pharmaceutical Marketing & Management. 16(1). 3–7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact